B. Metzler Seel. Sohn & Co. Ag Madrigal Pharmaceuticals, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $11.2 Billion
- Q3 2025
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 1,221 shares of MDGL stock, worth $646,165. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,221Holding current value
$646,165% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding MDGL
# of Institutions
407Shares Held
23.1MCall Options Held
666KPut Options Held
514K-
Baker Bros. Advisors LP New York, NY2.14MShares$1.13 Billion8.0% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$1.06 Billion12.22% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny1.91MShares$1.01 Billion31.28% of portfolio
-
Janus Henderson Group PLC London, X01.84MShares$975 Million0.41% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.83MShares$970 Million11.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $9.05B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...